Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?

Imagem de Miniatura
Arquivos
art_GIRARDI_SecondLine_Treatment_for_Advanced_Pancreatic_Adenocarcinoma_Is_There_2019.PDF.pdf (627.71 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
GIRARDI, Daniel M.
FARIA, Luiza Dib B. B.
TEIXEIRA, Marcela C.
COSTA, Frederico P.
FERNANDES, Gustavo S.
Citação
JOURNAL OF GASTROINTESTINAL CANCER, v.50, n.4, p.860-866, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose Advanced pancreatic adenocarcinoma (PA) is an aggressive disease that has poor prognosis and frequently interferes with patient's quality of life. There has been progress in first-line regimens; however, there is no standard second-line regimen. The aim of this study is to analyze second-line gemcitabine after first-line fluorouracil (FU) + leucovorin (LV) + irinotecan + oxaliplatin (FOLFIRINOX) regimen. Methods This study included consecutive patients with advanced PA treated at Hospital Sirio-Libanes from 2011 to 2016. The patients received FOLFIRINOX as first-line treatment and upon progression, received gemcitabine alone. Survival analysis was performed using the Kaplan-Meier method. Results A total of 54 patients were evaluated. Most patients were male (61.1%) and most had an ECOG performance status of 0 or 1 prior to the beginning of second-line treatment (66.6%). The mean number of gemcitabine cycles was 3.4. Most patients had disease progression as the best response to treatment (75.9%), 11.1% had stable disease, and 9.3% experienced a partial response. The median progression-free survival was 1.7 months, and the median overall survival was 6.8 months. Conclusions Gemcitabine alone did not show meaningful clinical benefit as second-line treatment after FOLFIRINOX.
Palavras-chave
Gemcitabine, FOLFIRINOX, Second-line treatment, Pancreatic
URI
https://observatorio.fm.usp.br/handle/OPI/35437
Referências
  1. Bertocchi P, 2015, REV RECENT CLIN TRIA, V10, P142, DOI 10.2174/1574887110666150417115303
  2. Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
  3. Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
  4. Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
  5. Gilabert M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006544
  6. Gill S, 2016, J CLIN ONCOL, V34, P3914, DOI 10.1200/JCO.2016.68.5776
  7. Lino AD, 2015, J GASTROINTEST ONCOL, V6, P511, DOI 10.3978/j.issn.2078-6891.2015.041
  8. Nguyen KT, 2017, J GASTROINTEST ONCOL, V8, P556, DOI 10.21037/jgo.2017.01.23
  9. Oettle H, 2014, J CLIN ONCOL, V32, P2423, DOI 10.1200/JCO.2013.53.6995
  10. Popp FC, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3186-8
  11. Portal A, 2015, BRIT J CANCER, V113, P989, DOI 10.1038/bjc.2015.328
  12. Sarabi M, 2017, ONCOL LETT, V13, P4917, DOI 10.3892/ol.2017.6061
  13. Viaud J, 2017, DIGEST LIVER DIS, V49, P692, DOI 10.1016/j.dld.2017.02.007
  14. Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369
  15. Wang-Gillam A, 2016, LANCET, V387, P545, DOI 10.1016/S0140-6736(15)00986-1
  16. Yip D, 2009, COCHRANE DB SYST REV, V07
  17. Zhang Y, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0025-y

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03